PharmaEngine, Inc. (4162) AI Stock Analysis

PharmaEngine, Inc.

(TPEx:4162)

Select Model

Rating:70Outperform

Price Target:TWD 58.00▲(10.48% Upside)

Action:initiatedcoverage

Date:11/10/26

The score is supported primarily by the exceptionally strong balance sheet and cash generation, with valuation also favorable. These strengths are offset by sharply declining revenue, weaker profitability, and technically bearish price momentum.

Positive Factors

Low LeverageMinimal leverage limits fixed financial obligations and reduces balance-sheet risk during periods of weaker operating performance. The equity-heavy structure also preserves flexibility to fund development, commercialization, or partnerships without relying heavily on additional borrowing.

Negative Factors

Revenue VolatilityThe sharp reversal from outsized 2024 growth to an approximately 64% revenue decline in 2025 makes near-term earnings power difficult to forecast. Such volatility can weaken planning visibility and raises concerns about the durability and concentration of revenue sources.

PharmaEngine, Inc. (4162) vs. SPDR S&P 500 ETF (SPY)

Market Cap: TWD 7.67B
Dividend Yield: 3.81%
Average Volume (3M): 268.95K
Price to Earnings (P/E): 14.2
Beta (1Y): 0.42
Revenue Growth: -58.69%
EPS Growth: -66.96%
Country: TW
Employees: 45
Sector: General
Sector Strength: 55
Industry: Biotechnology

PharmaEngine, Inc. Business Overview & Revenue Model

Company Description

PharmaEngine, Inc. is a biopharmaceutical firm specializing in the creation and advancement of oncology therapeutics, primarily targeting markets in Taiwan and Europe. Its leading drug candidate is ONIVYDE, an innovative liposomal formulation of irin...

PharmaEngine, Inc. Financial Statement Overview

Summary

Strong balance sheet and excellent cash generation support the score, but the 63.6% revenue decline and weakening margins indicate significant operating volatility.

Income Statement

55Neutral

Balance Sheet

90Very Positive

Cash Flow

94Very Positive

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.03B	911.42M	2.52B	767.67M	654.38M	654.84M
Gross Profit	959.62M	849.51M	2.48B	718.97M	604.68M	617.76M
EBITDA	635.99M	519.48M	2.17B	347.31M	401.15M	555.87M
Net Income	538.80M	387.64M	1.75B	274.65M	318.78M	426.03M
Balance Sheet
Total Assets	5.42B	5.15B	5.85B	3.95B	3.97B	4.03B
Cash, Cash Equivalents and Short-Term Investments	5.07B	4.72B	3.86B	3.63B	3.66B	3.81B
Total Debt	37.78M	42.12M	7.14M	14.81M	22.35M	7.59M
Total Liabilities	512.25M	221.59M	448.01M	91.01M	94.47M	87.70M
Stockholders Equity	4.91B	4.93B	5.40B	3.86B	3.87B	3.94B
Cash Flow
Free Cash Flow	540.31M	1.73B	455.32M	256.56M	198.07M	929.44M
Operating Cash Flow	540.65M	1.73B	456.73M	256.97M	202.01M	929.67M
Investing Cash Flow	-1.26B	-266.65M	-115.54M	-855.48M	-188.12M	-107.00M
Financing Cash Flow	-870.61M	-870.37M	-223.11M	-294.73M	-395.71M	-507.00M

PharmaEngine, Inc. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

TW:4162 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TW:4162	70Outperform	TWD 7.43B	14.16	―	3.81%	-58.69%	-66.96%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
TW:4169	54Neutral	TWD 7.93B	-291.25	―	0.27%	―	―
TW:4128	44Neutral	TWD 7.85B	24.61	―	―	4.85%	―
TW:6541	43Neutral	TWD 7.47B	-5.03	-26.61%	―	207.37%	4.17%

* General Sector Average

Performance Comparison

TW:4162 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TW:4162	PharmaEngine, Inc.	52.50	-17.18	-24.66%
TW:6541	Tanvex Biopharma	28.15	-27.35	-49.28%
TW:4128	Microbio Co., Ltd.	13.45	-6.85	-33.74%
TW:4169	TCM Biotech International Corp.	116.50	-63.27	-35.20%
TW:6976	Acepodia, Inc.	12.00	-3.30	-21.57%
TW:7876	Obigen Pharma, Inc.	66.20	29.51	80.45%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 09, 2026

PharmaEngine, Inc. AI Stock Analysis